Latest & greatest articles for losartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on losartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on losartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for losartan

1. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis. (Full text)

The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis. Variable effects of beta-blockers (BB) and/or angiotensin receptor blockers (ARB) were reported to retard aortic root growth in Marfan syndrome (MFS). This study aimed to compare the effects of BB therapy and ARB-related therapies on cardiovascular protection in MFS.Studies of randomized control trials comparing the efficacy of only-BB and ARB-related (only-ARB

2020 Journal of the Formosan Medical Association = Taiwan yi zhi PubMed abstract

2. Losartan for Preventing Aortic Root Dilatation in Patients with Marfan Syndrome: A Meta-Analysis of Randomized Trials. (Full text)

Losartan for Preventing Aortic Root Dilatation in Patients with Marfan Syndrome: A Meta-Analysis of Randomized Trials. The role of losartan in preventing aortic root dilatation in Marfan syndrome has been evaluated in many clinical trials; however, the results are conflicting.We performed a computerized search of MEDLINE, EMBASE and COCHRANE databases through February 2019 for randomized clinical trials evaluating the effect of losartan in patients with Marfan syndrome. The main outcome (...) was the change in the aortic root diameter in the losartan versus control groups.Our final analysis included seven randomized trials with a total of 1352 patients and average weighted follow-up of 37.8 months. Change in aortic root diameter was significantly smaller with losartan compared with control [weighted means: 0.44 vs. 0.58 mm, mean difference (MD) = -0.13; 95% CI -0.24 to -0.02; p = 0.02]. Subgroup analysis according to the control group showed no significant subgroup interaction when comparing

2019 Cardiology and therapy PubMed abstract

3. Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. (Abstract)

Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. 31260329 2019 07 10 2047-4881 2019 Jul 01 European journal of preventive cardiology Eur J Prev Cardiol Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. 2047487319861231 10.1177/2047487319861231 Li Lin L 1 Department of Medicine, John H Stroger Jr Hospital of Cook County, Chicago, USA. Yamani Naser N 2 Department of Medicine

2019 European journal of preventive cardiology

4. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome (Full text)

Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome Beta-blockers are the standard treatment in Marfan syndrome (MFS). Recent clinical trials with limited follow-up yielded conflicting results on losartan's effectiveness in MFS.The present study aimed to evaluate the benefit of losartan compared with atenolol for the prevention of aortic dilation and complications in Marfan patients over a longer observation period (>5 years).A total of 128 patients (...) included in the previous LOAT (LOsartan vs ATenolol) clinical trial (64 in the atenolol and 64 in the losartan group) were followed up for an open-label extension of the study, with the initial treatment maintained.Mean clinical follow-up was 6.7 ± 1.5 years. A total of 9 events (14.1%) occurred in the losartan group and 12 (18.8%) in the atenolol group. Survival analysis showed no differences in the combined endpoint of need for aortic surgery, aortic dissection, or death (p = 0.462). Aortic root

2018 EvidenceUpdates PubMed abstract

5. Losartan

Losartan Top results for losartan - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for losartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

6. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy (Full text)

Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested (...) a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot.The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired

2018 EvidenceUpdates PubMed abstract

7. The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials. (Abstract)

The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials. To assess the effect of losartan therapy on progressive aortic dilatation and on clinical outcome in patients with Marfan's syndrome (MFS).The meta-analysis was instituted, which included studies identified by a systematic review of MEDLINE of peer-reviewed publications. Echocardiogram or MRI measurements of the aortic root dimension and outcome (...) measures of death, cardiovascular surgery and aortic dissection or rupture were compared between patients who were treated and untreated with losartan therapy.Six randomized trials with 1398 subjects met all the inclusion criteria and were included in the meta-analysis. Compared with non-losartan treatment, losartan therapy significantly decreased the rate of aortic dilatation (SMD=-0.13 with 95% CI -0.25 to 0.00, p=0.04). The clinical outcome beneficial was not observed in the losartan treatment group

2016 International journal of cardiology

8. Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. (Abstract)

Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. Both enalapril and losartan are effective and widely used in patients with chronic kidney disease (CKD). This review aimed to evaluate the benefits of enalapril and losartan in adults with CKD.PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched, without language limitations, for randomized controlled trials (RCT), in which enalapril and losartan were compared in adults (...) with CKD. Standard methods, consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, were used. Reviewer Manager software, ver. 5.2, was used for meta-analysis.Of 318 citations retrieved, 17 RCT (14 parallel-group and three cross-over) met our inclusion criteria. The pooled analysis for parallel RCT showed that the effects of enalapril and losartan on blood pressure, renal function and serum uric acid (UA) were similar. Meta-analysis indicated

2015 Nephrology (Carlton, Vic.)

9. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. (Abstract)

Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. Many studies have compared losartan with other antihypertensive agents in the management of hypertensive patients with hyperuricaemia in China. However, systematic assessment of efficacy and safety between losartan and other antihypertensive agents is still lacking. This meta-analysis sought to evaluate the available randomized controlled trials (RCTs) regarding losartan treatment (...) for hypertensive patients with hyperuricaemia in China.Cochrane Library, PubMed, EMBASE, Chinese National Knowledge Infrastructure, and Wanfang database were searched until December 2013. Only RCTs comparing losartan with other antihypertensive agents for the management of hypertensive patients with hyperuricaemia in Chinese patients were included.Thirty-one RCTs with 2754 patients were identified. Losartan reduced serum uric acid levels (weighted mean differences  - 1.57 mg/dl, 95% confidence interval -1.83

2015 Journal of Hypertension

10. Atenolol versus losartan in children and young adults with Marfan's syndrome. (Full text)

Atenolol versus losartan in children and young adults with Marfan's syndrome. Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers.We conducted a randomized trial comparing losartan with atenolol in children and young adults with Marfan's syndrome. The primary outcome was the rate of aortic-root enlargement (...) months to 25 years of age (mean [±SD] age, 11.5±6.5 years in the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-root z score greater than 3.0. The baseline-adjusted rate of change in the mean (±SE) aortic-root z score did not differ significantly between the atenolol group and the losartan group (-0.139±0.013 and -0.107±0.013 standard-deviation units per year, respectively; P=0.08). Both slopes were significantly less than zero, indicating a decrease in the aortic-root

2014 NEJM Controlled trial quality: predicted high PubMed abstract

11. Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials. (Abstract)

Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials. Data from four clinical trials compared reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) among patients treated with amlodipine/losartan 5/50 mg vs 5/100 mg and amlodipine/losartan 5/50 mg vs amlodipine 5 mg and 10 mg. Response rate was assessed as reduction in SBP or DBP (>20/10 (...) mm Hg) and proportion of patients achieving SBP <140 mm Hg or DBP <90 mm Hg. Patients were grouped into quartiles based on baseline SBP and DBP. Mean SBP and DBP were reduced in amlodipine/losartan 5/50 mg (n=182) and amlodipine/losartan 5/100 mg (n=95) users across all baseline quartiles. Patients using amlodipine/losartan 5/50 mg had significantly greater SBP and DBP reductions vs amlodipine 5 mg (P=.001 and P=.02, respectively). Amlodipine/losartan 5/50 mg users had significantly greater SBP

2014 Journal of clinical hypertension (Greenwich, Conn.)

12. Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. (Abstract)

Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. This study compared blood pressure (BP) changes after 8 weeks of therapy between a fixed-dose combination (FDC) of amlodipine/losartan and amlodipine/valsartan using a network meta-analysis because no trials directly compared amlodipine/losartan with other FDCs.A systematic search identified six randomised controlled trials (amlodipine/losartan-3, amlodipine (...) /valsartan-3) of FDCs and their component monotherapies. Conventional fixed-effects methods were used to conduct the comparisons. The primary and secondary effect measures were the changes in sitting diastolic and systolic blood pressure (sitDBP, sitSBP) at 8 weeks post-randomisation.The estimated amlodipine/valsartan - amlodipine/losartan difference (95% confidence interval) in sitDBP reduction was -1.27 mmHg, (-5.7, 2.2) for lower dosages and -0.45 mmHg, (-3.7, 2.7) for higher dosages; for sitSBP

2014 International journal of clinical practice

13. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. (Abstract)

A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. Candesartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker (ARB). Several clinical trials have compared candesartan with losartan in the management of essential hypertension. However, systematic assessment of efficacy and safety between candesartan and losartan is still lacking.We reviewed randomised controlled trials (RCTs) comparing candesartan (...) with losartan for net reduction in blood pressure from baseline, response and control rates, and incidences of common and serious adverse events.Weighted mean differences (WMD), and relative risk (RR) with 95% confidence intervals (CI) were calculated for continuous and dichotomous data, respectively.A total of 12 RCTs with 3644 patients were included in this meta-analysis. When comparing the efficacy of candesartan and losartan in reducing systolic blood pressure (SBP) and diastolic blood pressure (DBP

2013 Journal of the renin-angiotensin-aldosterone system : JRAAS

14. A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. (Full text)

A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. A previous meta-analysis of a few randomized controlled trials (RCTs) suggests a significant reduction in ambulatory blood pressure (BP) with telmisartan as compared with losartan monotherapy. We performed an updated meta-analysis of RCTs of telmisartan versus losartan therapy for reduction of ambulatory BP in patients with hypertension. MEDLINE, EMBASE and the Cochrane Central (...) Register of Controlled Trials were searched through July 2012 using PubMed and OVID. Eligible studies were RCTs of telmisartan versus valsartan therapy enrolling individuals with hypertension and reporting ambulatory BP as an outcome. For each study, data regarding changes from baseline in ambulatory (24 h, last 6 h, morning, daytime and nighttime) BP in both the telmisartan and losartan groups were used to generate mean differences (MDs) and 95% confidence intervals (CIs). Of 34 potentially relevant

2013 Hypertension research : official journal of the Japanese Society of Hypertension PubMed abstract

15. Losartan and enalapril are comparable in reducing proteinuria in children (Full text)

Losartan and enalapril are comparable in reducing proteinuria in children Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers delay progression of chronic kidney disease and have antiproteinuric effects beyond their effects on blood pressure. They are routinely used in adults; however, their efficacy and safety in children, in whom the causes of chronic kidney disease are significantly different relative to adults, is uncertain. Here we assessed an open-label (...) extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria. In this study, 268 children were re-randomized to losartan or enalapril and followed until 100 patients completed 3 years of follow-up for proteinuria and renal function. The least squares percent mean reduction from baseline in the urinary protein/creatinine ratio was 30.01% for losartan and 40.45

2013 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

16. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. (Full text)

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. 22124433 2012 02 07 2018 12 01 1524-4563 59 1 2012 Jan Hypertension (Dallas, Tex. : 1979) Hypertension Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus (...) with the Angiotensin II Antagonist Losartan Trial. e1 10.1161/HYPERTENSIONAHA.111.186064 Dhaun Neeraj N Webb David J DJ eng Letter Comment 2011 11 28 United States Hypertension 7906255 0194-911X 0 Angiotensin II Type 1 Receptor Blockers 268B43MJ25 Uric Acid JMS50MPO89 Losartan IM Hypertension. 2011 Jul;58(1):2-7 21632472 Angiotensin II Type 1 Receptor Blockers administration & dosage Diabetes Mellitus, Type 2 blood Diabetic Nephropathies prevention & control Female Glomerular Filtration Rate drug effects Humans

2012 Hypertension (Dallas, Tex. : 1979) Controlled trial quality: uncertain PubMed abstract

17. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching (Full text)

Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Baker TM, Goh J, Johnston A, Falvey H, Brede Y, Brown RE Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of valsartan, compared with losartan, and the impact of switching patients from valsartan to generic losartan, to lower blood pressure and prevent cardiovascular disease. The authors concluded that valsartan appeared to be cost-effective, compared with switching to generic losartan. Overall the quality of the study was adequate

2012 NHS Economic Evaluation Database. PubMed abstract

18. Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure. (Abstract)

Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure. 21762314 2011 12 23 2018 12 01 1742-1241 65 8 2011 Aug International journal of clinical practice Int. J. Clin. Pract. Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure. 911; author reply 912 10.1111/j.1742-1241.2011.02700.x Meredith P A PA Jarvis S C SC eng Letter Comment England Int J Clin (...) Pract 9712381 1368-5031 0 Angiotensin II Type 1 Receptor Blockers 0 Benzimidazoles 0 Tetrazoles JMS50MPO89 Losartan IM Int J Clin Pract. 2011 Mar;65(3):253-63 21284790 Angiotensin II Type 1 Receptor Blockers therapeutic use Benzimidazoles therapeutic use Female Heart Failure drug therapy Humans Hypertension drug therapy Losartan therapeutic use Male Tetrazoles therapeutic use 2011 7 19 6 0 2011 7 19 6 0 2011 12 24 6 0 ppublish 21762314 10.1111/j.1742-1241.2011.02700.x

2011 International journal of clinical practice

19. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis (Full text)

Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market. With the recent introduction of generic losartan, we set out to directly compare (...) the branded market leader to its now cheaper alternative. The primary objectives were to compare the blood pressure (BP) lowering efficacy and cardiovascular outcomes of candesartan and losartan in the treatment of essential hypertension and chronic heart failure, respectively. The secondary objective was to model their comparative incremental cost-effectiveness in a UK NHS setting. The Cochrane Central Register of Controlled Trials (Cochrane Library 2009, issue 2), which contains the Hypertension

2011 EvidenceUpdates PubMed abstract

20. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension

A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.